2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Lung Neoplasms
19
Melanoma
18
Neoplasm Metastasis
16
Carcinoma, Hepatocellular
15
Neoplasms
13
Esophageal Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Colorectal Neoplasms
9
Breast Neoplasms
9
Head and Neck Neoplasms
8
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Carcinoma, Renal Cell
6
Brain Neoplasms
6
Small Cell Lung Carcinoma
5
Recurrence
5
Pancreatic Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Liver Neoplasms
4
Glioblastoma
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Nasopharyngeal Carcinoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Interventions
Ipilimumab
17
tremelimumab
9
Nivolumab
9
durvalumab
8
pembrolizumab
6
Paclitaxel
5
Carboplatin
4
Capecitabine
4
Bevacizumab
4
lenvatinib
3
spartalizumab
2
balstilimab
2
Radiotherapy
2
Radiation
2
Pemetrexed
2
Oxaliplatin
2
Doxorubicin
2
Docetaxel
2
Cisplatin
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tilsotolimod
1
tebentafusp
1
relatlimab
1
poly ICLC
1
osimertinib
1
folfirinox
1
eribulin
1
envafolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Immunotherapy
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled